Global CAR T-cell Therapy Market 2018-2022| 63% CAGR Projection Over the Next Four Years | Technavio
LONDON--(BUSINESS WIRE)--Oct 4, 2018-- analysts forecast the global CAR T-cell therapy market to grow at a CAGR of over 63% during the forecast period, according to their latest market research report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181004005540/en/
Technavio analysts forecast the global CAR T-cell therapy market to grow at a CAGR of over 63% by 2022. (Graphic: Business Wire)
The collaborative R&D efforts are one of the major trends being witnessed in the . The majority of therapies in the global CAR T-cell therapy market are still in the early stages of clinical trials. Currently, the research is dominated by the biotech companies, which do not receive huge funding required to carry out the research completely. These companies license out molecules or technology platforms to the pharmaceutical companies or collaborate with them or various research programs.
According to Technavio analysts, one of the key factors contributing to the growth of the global CAR T-cell therapy market is the proven effectiveness of CAR T-cell therapy:
Global CAR T-cell therapy market: Proven effectiveness of CAR T-cell therapy
CAR-T cell therapies are proven to have higher efficacy than other therapies that are currently available in the market for the treatment of cancer. The ability of CAR to bind to the T-cell, especially when delivered through monoclonal antibodies, results in the easy penetration of cells into the cancer-causing cells in the patients.
According to a senior analyst at Technavio for research on infectious and rare diseases, “Novartis is developing Kymriah, a CAR T-cell therapy, for various other cancers such as CLL, multiple myeloma, and non-Hodgkin’s lymphoma, with the primary objective of the study being to increase effectiveness while reducing side effects of the therapy.”
Global CAR T-cell therapy market: Segmentation analysis
The global CAR T-cell therapy market research report provides market segmentation by antigen (CD19, CD22, and others) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
The CD19 segment held the largest market share in 2017, contributing to over 88% of the market. This antigen segment will dominate the global market throughout the forecast period.
The Americas held the largest share of the market in 2017, accounting for over 64% share, followed by EMEA and APAC, respectively. Although APAC held the smallest share of the market, it is expected to witness the maximum increase in its market share over the forecast period.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181004005540/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH ONCOLOGY RESEARCH SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 10/04/2018 11:12 AM/DISC: 10/04/2018 11:12 AM